His primary scientific interests are in Microbiology, Vancomycin, Antibiotics, Staphylococcus aureus and Antibacterial agent. He interconnects Enterococcus faecalis and Virulence in the investigation of issues within Microbiology. His Vancomycin study combines topics from a wide range of disciplines, such as Internal medicine, Nomogram, Surgery and Urology.
His research integrates issues of Immunology and Intensive care medicine in his study of Antibiotics. His Drug resistance research includes elements of Penicillin, Minimum inhibitory concentration and Virology. His work deals with themes such as Plasmid, Antimicrobial, Enterococcus faecium and Multilocus sequence typing, which intersect with Antibiotic resistance.
His scientific interests lie mostly in Microbiology, Antibiotics, Vancomycin, Antibacterial agent and Antimicrobial. His Microbiology study integrates concerns from other disciplines, such as Enterococcus faecalis and Staphylococcus aureus. His Antibiotics research is multidisciplinary, incorporating perspectives in Immunology, Drug resistance and Intensive care medicine.
His studies deal with areas such as Glycopeptide, Internal medicine and Surgery as well as Vancomycin. His Antibacterial agent study deals with Enterococcus faecium intersecting with Quinupristin/dalfopristin and Vancomycin-resistant Enterococcus. Robert C. Moellering works mostly in the field of Antimicrobial, limiting it down to concerns involving Multiple drug resistance and, occasionally, Antimicrobial stewardship.
Robert C. Moellering mainly focuses on Methicillin-resistant Staphylococcus aureus, Antibiotics, Staphylococcus aureus, Microbiology and Vancomycin. Robert C. Moellering has researched Methicillin-resistant Staphylococcus aureus in several fields, including Skin infection, Disease, Immunology and Intensive care medicine. His research in Antibiotics intersects with topics in Abscess, Pharmacotherapy and Drug resistance.
In his study, which falls under the umbrella issue of Staphylococcus aureus, Endocarditis, Staphylococcal infections, Pneumonia and Antibiotic resistance is strongly linked to Bacteremia. His work in the fields of Microbiology, such as Pathogen, intersects with other areas such as Eukaryote. The study incorporates disciplines such as Bacterial virulence, Therapeutic drug monitoring and Clinical trial in addition to Antibacterial agent.
The scientist’s investigation covers issues in Methicillin-resistant Staphylococcus aureus, Multiple drug resistance, Antimicrobial, Antibiotic resistance and Bacteremia. His study in Methicillin-resistant Staphylococcus aureus is interdisciplinary in nature, drawing from both Surgery, Disease and Family medicine. The various areas that Robert C. Moellering examines in his Antimicrobial study include Epistasis, Genetics and Drug.
His study looks at the relationship between Antibiotic resistance and topics such as Pneumonia, which overlap with Microbiology and Vancomycin. His Bacteremia research also works with subjects such as
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Howard S. Gold;Robert C. Moellering.
The New England Journal of Medicine (1996)
Relationship of MIC and Bactericidal Activity to Efficacy of Vancomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia
George Sakoulas;Pamela A. Moise-Broder;Jerome Schentag;Alan Forrest.
Journal of Clinical Microbiology (2004)
The Sanford guide to antimicrobial therapy
David N. Gilbert;Robert C. Moellering;George M. Eliopoulos;Henry F. Chambers.
Emergence of Enterococcus as a Significant Pathogen
Robert C. Moellering.
Clinical Infectious Diseases (1992)
The Rationale for Revising the Clinical and Laboratory Standards Institute Vancomycin Minimal Inhibitory Concentration Interpretive Criteria for Staphylococcus aureus
Fred C. Tenover;Robert C. Moellering.
Clinical Infectious Diseases (2007)
Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility.
L B Rice;S H Willey;G A Papanicolaou;A A Medeiros.
Antimicrobial Agents and Chemotherapy (1990)
Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.
Michael J. Rybak;Michael J. Rybak;Ben M. Lomaestro;John C. Rotschafer;Robert C. Moellering.
Linezolid: The first oxazolidinone antimicrobial
Robert C. Moellering.
Annals of Internal Medicine (2003)
Accessory Gene Regulator Group II Polymorphism in Methicillin-Resistant Staphylococcus aureus Is Predictive of Failure of Vancomycin Therapy
Pamela A. Moise-Broder;George Sakoulas;George M. Eliopoulos;Jerome J. Schentag.
Clinical Infectious Diseases (2004)
Increasing Antibiotic Resistance among Methicillin-Resistant Staphylococcus aureus Strains
George Sakoulas;Robert C. Moellering.
Clinical Infectious Diseases (2008)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: